MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 562498 | Name: Citicoline
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Citicoline is a neuroprotective agent. It acts by enhancing cellular communication, stimulating the synthesis of SAMe, and increasing glucose metabolism.

Chemical Structure

Citicoline
Citicoline
CAS#987-78-0 (free)

Theoretical Analysis

MedKoo Cat#: 562498

Name: Citicoline

CAS#: 987-78-0 (free)

Chemical Formula: C14H26N4O11P2

Exact Mass: 488.1000

Molecular Weight: 488.32

Elemental Analysis: C, 34.43; H, 5.37; N, 11.47; O, 36.04; P, 12.69

Price and Availability

Size Price Availability Quantity
5g USD 250.00 2 Weeks
25g USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
987-78-0 (free) 33818-15-4 (sodium)
Synonym
Citicoline; Cytidine 5-diphosphocholine; Cdp-choline; Cdp choline; citicoline; CDP-choline(1+); CDP-choline; Nicholin
IUPAC/Chemical Name
2-(((((((2S,3R,4S,5S)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)oxidophosphoryl)oxy)-N,N,N-trimethylethan-1-aminium
InChi Key
RZZPDXZPRHQOCG-BQUFFADESA-N
InChi Code
InChI=1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/t9-,11-,12-,13-/m0/s1
SMILES Code
C[N+](CCOP(OP(O)(OC[C@@H]1O[C@H](N2C=CC(N)=NC2=O)[C@@H](O)[C@H]1O)=O)([O-])=O)(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 488.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Iulia C, Ruxandra T, Costin LB, Liliana-Mary V. Citicoline - a neuroprotector with proven effects on glaucomatous disease. Rom J Ophthalmol. 2017 Jul-Sep;61(3):152-158. Review. PubMed PMID: 29450391; PubMed Central PMCID: PMC5710031. 2: Farooq MU, Min J, Goshgarian C, Gorelick PB. Pharmacotherapy for Vascular Cognitive Impairment. CNS Drugs. 2017 Sep;31(9):759-776. doi: 10.1007/s40263-017-0459-3. Review. PubMed PMID: 28786085. 3: Agarwal S, Patel BM. Is aura around citicoline fading? A systemic review. Indian J Pharmacol. 2017 Jan-Feb;49(1):4-9. doi: 10.4103/0253-7613.201037. Review. PubMed PMID: 28458415; PubMed Central PMCID: PMC5351236. 4: Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol. 2016 Dec 23;63(S03):S1-S73. Review. Spanish, English. PubMed PMID: 28417449. 5: Karsy M, Brock A, Guan J, Taussky P, Kalani MY, Park MS. Neuroprotective strategies and the underlying molecular basis of cerebrovascular stroke. Neurosurg Focus. 2017 Apr;42(4):E3. doi: 10.3171/2017.1.FOCUS16522. Review. PubMed PMID: 28366066. 6: Salloum IM, Brown ES. Management of comorbid bipolar disorder and substance use disorders. Am J Drug Alcohol Abuse. 2017 Jul;43(4):366-376. doi: 10.1080/00952990.2017.1292279. Epub 2017 Mar 16. Review. PubMed PMID: 28301219. 7: Chen X, Qiu H, Wang C, Yuan Y, Tickner J, Xu J, Zou J. Molecular structure and differential function of choline kinases CHKα and CHKβ in musculoskeletal system and cancer. Cytokine Growth Factor Rev. 2017 Feb;33:65-72. doi: 10.1016/j.cytogfr.2016.10.002. Epub 2016 Oct 8. Review. PubMed PMID: 27769579. 8: El Sayed I, Zaki A, Fayed AM, Shehata GM, Abdelmonem S. A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury. Neurosurg Rev. 2018 Apr;41(2):427-438. doi: 10.1007/s10143-016-0775-y. Epub 2016 Aug 18. Review. PubMed PMID: 27539610. 9: Secades JJ, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Martínez-Vila E, Ríos J, Oudovenko N. Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. J Stroke Cerebrovasc Dis. 2016 Aug;25(8):1984-96. doi: 10.1016/j.jstrokecerebrovasdis.2016.04.010. Epub 2016 May 24. Review. PubMed PMID: 27234918. 10: Grieb P, Jünemann A, Rekas M, Rejdak R. Citicoline: A Food Beneficial for Patients Suffering from or Threated with Glaucoma. Front Aging Neurosci. 2016 Apr 8;8:73. doi: 10.3389/fnagi.2016.00073. eCollection 2016. Review. PubMed PMID: 27092075; PubMed Central PMCID: PMC4824764. 11: Solovieva EY, Farrahova KI, Karneev AN, Chipova DT. [Phospholipids metabolism disorders in acute stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(1):104-112. doi: 10.17116/jnevro201611611104-112. Review. Russian. PubMed PMID: 27045147. 12: Siddiqi N, Harrison JK, Clegg A, Teale EA, Young J, Taylor J, Simpkins SA. Interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev. 2016 Mar 11;3:CD005563. doi: 10.1002/14651858.CD005563.pub3. Review. PubMed PMID: 26967259. 13: Gore C, Wu C. Medical Therapies of Amblyopia: Translational Research to Expand Our Treatment Armamentarium. Semin Ophthalmol. 2016;31(1-2):155-8. doi: 10.3109/08820538.2015.1114851. Review. PubMed PMID: 26959141. 14: Schmidt A, Minnerup J. Promoting recovery from ischemic stroke. Expert Rev Neurother. 2016;16(2):173-86. doi: 10.1586/14737175.2016.1134324. Epub 2016 Jan 11. Review. PubMed PMID: 26689223. 15: Roberti G, Tanga L, Michelessi M, Quaranta L, Parisi V, Manni G, Oddone F. Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives. Int J Mol Sci. 2015 Nov 30;16(12):28401-17. doi: 10.3390/ijms161226099. Review. PubMed PMID: 26633368; PubMed Central PMCID: PMC4691046. 16: Tuttolomondo A, Pecoraro R, Arnao V, Maugeri R, Iacopino DG, Pinto A. Developing drug strategies for the neuroprotective treatment of acute ischemic stroke. Expert Rev Neurother. 2015;15(11):1271-84. doi: 10.1586/14737175.2015.1101345. Epub 2015 Oct 15. Review. PubMed PMID: 26469760. 17: Gareri P, Castagna A, Cotroneo AM, Putignano S, De Sarro G, Bruni AC. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clin Interv Aging. 2015 Sep 3;10:1421-9. doi: 10.2147/CIA.S87886. eCollection 2015. Review. Erratum in: Clin Interv Aging. 2015;10:1625. PubMed PMID: 26366063; PubMed Central PMCID: PMC4562749. 18: Wu S, Kutlubaev MA, Chun HY, Cowey E, Pollock A, Macleod MR, Dennis M, Keane E, Sharpe M, Mead GE. Interventions for post-stroke fatigue. Cochrane Database Syst Rev. 2015 Jul 2;(7):CD007030. doi: 10.1002/14651858.CD007030.pub3. Review. PubMed PMID: 26133313. 19: Martynov MY, Gusev EI. Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. J Exp Pharmacol. 2015 Oct 1;7:17-28. doi: 10.2147/JEP.S63544. eCollection 2015. Review. PubMed PMID: 27186142; PubMed Central PMCID: PMC4863531. 20: Wignall ND, Brown ES. Citicoline in addictive disorders: a review of the literature. Am J Drug Alcohol Abuse. 2014 Jul;40(4):262-8. doi: 10.3109/00952990.2014.925467. Epub 2014 Jun 20. Review. PubMed PMID: 24950234; PubMed Central PMCID: PMC4139283.